.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, people along with metastatic stomach lumps that acquired biomarker-matched therapies based upon flowing cyst DNA profiling showed a higher clinical perk than those receiving incomparable treatment.